ReviewFrontiers in oncology2020
Meningioma: A Review of Clinicopathological and Molecular Aspects.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Association Between miRNAs and the Diagnosis, Prognosis, and Recurrence of Patients with Meningioma: A Systematic Review.Cellular and molecular neurobiology · 2026Pooled it
- Late surgical site hemorrhage is a possible radiologic indicator of early tumor recurrence in grossly totally resected high-grade meningioma: A case report.Radiology case reports · 2026Article
- Article
- Automated deep learning-based segmentation and volumetric analysis of meningiomas.Neuroradiology · 2026Article
- Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026Review
- Article
- [Pediatric parasagittal meningioma, case report].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) dataset.Scientific data · 2026Article
- Review
- A Two-way Mendelian randomisation study of inflammatory factors and the risk of meningioma.Translational neuroscience · 2026Article
- Unilateral Parietal Bone Thickening in a Young Female Donor With a History of a Malignant Brain Neoplasm.Cureus · 2025Article
- Article
- Conserved methylation signature accurately predicts heavily irradiated CNS tumour with perplexing histopathology: A case report.Biomedical reports · 2025Article
- Correlation ofInternational journal of molecular sciences · 2025Article
- In Silico Identification of circPIM1/miR-16-5p/miR-195-5p/PIM1 Feed-Forward Loop in Recurrent Grade 2 Meningioma.International journal of molecular sciences · 2025Article
- Review
- ADAM12 Silencing Mediated by FOXC2 Represses Meningioma Progression Through Inactivating the JAK1/STAT3/VEGFA Pathway.Biochemical genetics · 2025Article
- Distinguishing Intracranial Solitary Fibrous Tumors from Meningiomas: The Diagnostic Value of T1-Weighted MRI Signal Intensity and ADC Values.AJNR. American journal of neuroradiology · 2025Article
- Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas.EBioMedicine · 2025Article
- Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.Neuro-oncology advances · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. They classically are found to be more common in females, with the exception of higher grades that have a predilection for males, and patients of older age. Meningiomas can also be seen as a spectrum of inherited syndromes such as neurofibromatosis 2 as well as ionizing radiation. In general, the 5-year survival for a WHO grade I meningioma exceeds 80%; however, survival is greatly reduced in anaplastic meningiomas. The standard of care for meningiomas in a surgically-accessible location is gross total resection. Radiation therapy is generally saved for atypical, anaplastic, recurrent, and surgically inaccessible benign meningiomas with a total dose of ~60 Gy. However, the method of radiation, regimen and timing is still evolving and is an area of active research with ongoing clinical trials. While there are currently no good adjuvant chemotherapeutic agents available, recent advances in the genomic and epigenomic landscape of meningiomas are being explored for potential targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.